The purpose of the Keynote breast cancer clinical trials is to see if the investigational drug, pembrolizumab, will slow down or stop the growth of breast cancer cells.
Pembrolizumab is an investigational immunotherapy that may help the body’s immune system attack cancer cells. When a cancer cell binds to an immune cell, the immune cell can’t do its job. These trials want to see if pembrolizumab can block cancer cells from binding with immune cells to help allow the immune cells to work properly.
Triple negative breast cancer represents 15-20% of all breast cancers. A triple negative breast cancer diagnosis means that the cancer cells have tested negative for three different receptors that are commonly found on breast cancer cells: the estrogen receptor (ER), the progesterone receptor (PR) and the human epidermal growth factor (HER-2). When these receptors are not present on the cell, non-chemotherapy treatments that block these receptors, such as hormone therapy or targeted therapy, do not work and the only treatment available is chemotherapy.
Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.You can also call our clinical trial information center at 1-888-577-8839 to learn more.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Study of Pembrolizumab Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer||355||Triple Negative Breast Cancer (TNBC)||Phase 3||Recruiting|
|Study of Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer||522||Triple Negative Breast Neoplasms||Phase 3||Recruiting|
|Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer||119||Metastatic Triple Negative Breast Cancer||Phase 3||Active, not recruiting|
|Study of Pembrolizumab Monotherapy for Metastatic Triple-Negative Breast Cancer||086||Breast Cancer||Phase 2||Active, not recruiting|
|Safety and Efficacy Study of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer||173||Triple Negative Breast Neoplasms||Phase 1||Active, not recruiting|
There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.